Artwork
iconShare
 
Manage episode 299854748 series 2738732
Content provided by Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Greg Kubin & Matias Serebrinsky, Greg Kubin, and Matias Serebrinsky or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Episode 10 features Lars Wilde, co-founder and Chief Business Officer of Compass Pathways, a mental health company with an initial focus on psilocybin therapy for Treatment-Resistant Depression.
In this episode, we discuss:

  • Lars’ experience overcoming Treatment-Resistant Depression with psilocybin
  • The nuances of clinical trials and psilocybin dosing protocols
  • Compass Pathways’ Intellectual Property strategy
  • What additional indications and therapies Compass Pathways is interested in

Links to topics discussed in this episode:
Compass Pathways, Lars Wilde
COMP360
SSRI, SNRI
Christian Angermayer, Robin Carhart-Harris, Michael Pollan
Vivaneo
Quercis Pharma
TRD (Therapy-Resistant Depression)
Compass Phase 2B Trial
Jazz Pharmaceuticals
Compass Pathways 2 US patents
Oregon Psilocybin Therapy Measure 109
Read the transcript here.
Watch episode 10 on YouTube.

Created by Greg Kubin and Matias Serebrinsky
Hosts: Matias Serebrinsky and Greg Kubin
Produced by Jonathan A. Davis & Zack Frank
Marketing by DaisyMae VanValkenburgh

Find us at businesstrip.fm
Follow us on Instagram and Twitter!

Theme music by Dorian Love
Additional music: River Meditation by Jason Shaw and Thea by Muted Circus

  continue reading

Chapters

1. Intro (00:00:00)

2. Welcome Lars Wilde (00:02:02)

3. Start of Interview (00:05:35)

4. Compass Origin Story (00:06:17)

5. Christian Angermayer (00:08:26)

6. Biotech Landscape (00:11:07)

7. Why biotech? (00:12:35)

8. Open about TRD (00:14:34)

9. Compass protocol & patient experience (00:17:01)

10. Integration Therapy (00:21:27)

11. Dosing in treatment (00:24:16)

12. COMP360 experience (00:27:23)

13. Who is part of the trials? (00:33:17)

14. Compass Model (00:34:47)

15. Applying COMP360 to other indications (00:37:09)

16. Cost of treatment (00:38:59)

17. COMP360 vs other companies (00:40:25)

18. Polymorphic vs. generic psilocybin (00:42:13)

19. Emerging psychedelic sector (00:46:16)

20. Jazz Pharmaceuticals (00:46:47)

21. Compass Patent Strategy (00:47:49)

22. Rapid fire questions (00:54:56)

23. Greg's Wrap Up (00:58:03)

24. Follow us on Twitter (00:58:03)

25. Follow us on Instagram (00:58:03)

60 episodes